Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cenicriviroc in Mild and Moderate Hepatic Impairment
NCT02120547Phase 1Completed
- Sponsor
- Tobira Therapeutics
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH) and human immunodeficiency virus infection (HIV) (3 arms), sponsored by Tobira Therapeutics. Primary endpoint: Multiple-dose pharmacokinetics of CVC at Day 14. Started Mar 2014; status: completed.
02
Drugs
cenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02120547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120547.